Investor Presentation

[Motilal Oswal Conference] Press Release - Q2FY27 - Revenue 45.52bn +13.8% y-y; EBITDA 10.25bn +11.3% y-y (margin 22.5%); PAT 6.75bn -11.7% y-y - India sales grew 9.5% with chronic segment outperforming IPM by 640 bps in Q2FY27 - US sales grew 2.4% YoY; Non-US international sales up 58%, excluding Occlutech 28.6% - R&D spend rose to 4.3% of revenue; MedTech sales include Occlutech from Q2FY27 - EBITDA margin declined 50 bps YoY due to Enzene CDMO costs and Occlutech acquisition - Net cash position strong at ₹49,054 mn as of Sept 30, 2026 - Facility inspections: Daman OAI with remediation ongoing; Mandva API plant cleared with zero observations